Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/128247
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis
Author: Mousa, A.
Løvvik, T.
Hilkka, I.
Carlsen, S.M.
Morin-Papunen, L.
Tertti, K.
Rönnemaa, T.
Syngelaki, A.
Nicolaides, K.
Shehata, H.
Burden, C.
Norman, J.E.
Rowan, J.
Dodd, J.M.
Hague, W.
Vanky, E.
Teede, H.J.
Citation: BMJ Open, 2020; 10(5):e036981-1-e036981-8
Publisher: BMJ
Issue Date: 2020
ISSN: 2044-6055
2044-6055
Statement of
Responsibility: 
Aya Mousa ... Janet Rowan, Jodie M Dodd, William Hague, Eszter Vanky, Helena J Teede ... et al.
Abstract: INTRODUCTION: Gestational diabetes mellitus (GDM) is a common disorder of pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used for the prevention and management of GDM; however, its use in pregnancy continues to be debated. The Metformin in Pregnancy Study aims to use individual patient data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in pregnancy and to identify relevant knowledge gaps. METHODS AND ANALYSIS: MEDLINE, EMBASE and all Evidence-Based Medicine will be systematically searched for randomised controlled trials (RCT) testing the efficacy of metformin compared with placebo, usual care or other interventions in pregnant women. Two independent reviewers will assess eligibility using prespecified criteria and will conduct data extraction and quality appraisal of eligible studies. Authors of included trials will be contacted and asked to contribute IPD. Primary outcomes include maternal glycaemic parameters and GDM, as well as neonatal hypoglycaemia, anthropometry and gestational age at delivery. Other adverse maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD from these RCTs will be harmonised and a two-step meta-analytic approach will be used to determine the efficacy and safety of metformin in pregnancy, with a priori adjustment for covariates and subgroups to examine effect moderators of treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias and the impact of trials which have not provided IPD. ETHICS AND DISSEMINATION: All IPD will be deidentified and studies contributing IPD will have ethical approval from their respective local ethics committees. This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality. Findings will be published in peer-reviewed journals and disseminated at scientific meetings, providing much needed evidence to inform clinical and public health actions in this area.
Keywords: diabetes in pregnancy
obstetrics
preventive medicine
reproductive medicine
Rights: © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
DOI: 10.1136/bmjopen-2020-036981
Grant ID: NHMRC
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_128247.pdfPublished version342.23 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.